dyslipidaemia
LDL is causal: each 1 mmol/L reduction → 20–22% relative risk reduction, so absolute benefit = baseline risk × how much LDL can fall. Statin-indicated conditions (ASCVD, AAA >3 cm, most diabetes, CKD not on dialysis, LDL ≥5.0) → statin without a risk score. Everyone else → FRS (or CLEM) every 5 years from 40–75: high (≥20%) treat; intermediate (10–19.9%) treat if LDL ≥3.5 or risk modifiers; low (<10%) lifestyle. Once on a maximally tolerated statin, CCS uses intensification thresholds, not targets: ASCVD LDL ≥1.8 (non-HDL ≥2.4, apoB ≥0.7) → ezetimibe and/or PCSK9 inhibitor; PCSK9 inhibitor first if far above threshold or a high-benefit group. TG >1.5 → use non-HDL or apoB, not LDL. Lp(a) once in a lifetime. TG 1.5–5.6 on statin with ASCVD (or diabetes + risk factor) → icosapent ethyl; OTC omega-3 does nothing.
who gets a statin
statin-indicated conditions — no risk score needed
| condition | criterion |
|---|---|
| ASCVD | MI/[[acute coronary syndromes |
| [[aortic aneurysm | AAA]] |
| diabetes | age ≥40, or ≥30 with ≥15 y duration, or microvascular disease |
| [[chronic kidney disease | CKD]] |
| LDL ≥5.0 mmol/L | or apoB ≥1.45 g/L or non-HDL ≥5.8 — presumed genetic (FH) |
primary prevention by FRS
Calculator: CCS Framingham Risk Score (also in the iCCS app).
| FRS (10-year) | statin if |
|---|---|
| high ≥20% | all |
| intermediate 10–19.9% | LDL ≥3.5 (non-HDL ≥4.2, apoB ≥1.05); or men ≥50 / women ≥60 with 1 extra risk factor (low HDL, IFG, high waist, smoking, HTN — HOPE-3 (2016)); or risk modifiers: hsCRP ≥2.0 mg/L, CAC >0, family history of premature CAD, Lp(a) ≥100 nmol/L |
| low 5–9.9% | LDL ≥3.5 (non-HDL ≥4.2, apoB ≥1.05), especially with risk modifiers — treat as intermediate |
| low <10% otherwise | lifestyle only |
- Premature family history (first-degree male ≤55, female ≤65) roughly doubles FRS in ages 30–59 without diabetes
- benefit likely continues >75 in primary prevention
- Lifestyle for all: Mediterranean-pattern diet, ≥150 min/week moderate–vigorous aerobic activity, smoking cessation
- Ontario: apoB and Lp(a) are not insured
CAC — when the decision is genuinely uncertain
- use: asymptomatic, ≥40 y, intermediate FRS, decision uncertain; not if high risk or already on a statin
- CAC 0 → reasonable to withhold statin except smokers, diabetes, FH/high Lp(a), strong family history (calcium appears late → CAC 0 reassures least <50 y and in women)
- CAC 1–99 → shared decision; CAC >100 → statin regardless of FRS
- don’t repeat CAC to monitor statin effect (statins can raise CAC)
thresholds for adding therapy
All on a maximally tolerated statin first — high-intensity (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) for all ASCVD (strong). Low or very low LDL on treatment → no down-titration.
| group | add therapy if | add |
|---|---|---|
| ASCVD | LDL ≥1.8 / non-HDL ≥2.4 / apoB ≥0.7 | algorithm below |
| diabetes, CKD (statin-indicated, no ASCVD) | LDL ≥2.0 / non-HDL ≥2.6 / apoB ≥0.8 | ezetimibe first (bile acid sequestrant alternative) |
| LDL ≥5.0 / FH without ASCVD | LDL ≥2.5 or <50% reduction / non-HDL ≥3.2 / apoB ≥0.85 | ezetimibe or PCSK9 inhibitor (strong for PCSK9i in heterozygous FH) |
| primary prevention, FRS-based | LDL ≥2.0 / non-HDL ≥2.6 / apoB ≥0.8, or <50% reduction | discuss ezetimibe |
flowchart TD
A[ASCVD on maximally tolerated statin] --> B{LDL ≥1.8 or non-HDL ≥2.4<br/>or apoB ≥0.7?}
B -- No --> C[Continue<br/>add-on may still be considered if very high risk]
B -- Yes --> D{LDL >2.2, non-HDL >2.9, apoB >0.8<br/>or high-benefit group?}
D -- No: LDL 1.8–2.2 --> E[Ezetimibe ± PCSK9 inhibitor]
D -- Yes --> F[PCSK9 inhibitor ± ezetimibe]
E -. still above threshold .-> F
A --> G{Fasting TG 1.5–5.6?}
G -- Yes --> H[Icosapent ethyl 2 g BID]
High-benefit groups for PCSK9 inhibitors (strong) — the subgroups with the largest absolute benefit in FOURIER/ODYSSEY:
- ACS within the past 52 weeks
- ASCVD plus any of: diabetes or metabolic syndrome, polyvascular disease (≥2 beds), symptomatic PAD, recurrent MI, MI within 2 years, prior CABG, LDL ≥2.6 or heterozygous FH, Lp(a) ≥120 nmol/L
Ezetimibe lowers LDL ~20% on top of a statin → can’t close a large gap; LDL >2.2 favours a PCSK9 inhibitor. Drug plans may still require an ezetimibe trial first.
non-statin agents
| agent | LDL ↓ | outcome evidence | notes |
|---|---|---|---|
| ezetimibe 10 mg | ~20% (with statin) | IMPROVE-IT (2015): ACS, HR 0.94, NNT 50 over 7 y | modest, slow-accruing benefit |
| PCSK9 inhibitor — evolocumab 140 mg SC q2wk / 420 mg monthly; alirocumab 75–150 mg SC q2wk | 50–70% | FOURIER (2017): HR 0.85, NNT 67 over 2.2 y; ODYSSEY OUTCOMES (2018): ACS 1–12 mo, HR 0.85 | no mortality benefit shown (short follow-up); injection-site reactions; also ↓ Lp(a) ~15–30% |
| icosapent ethyl 2 g BID | — (TG ↓ ~18%) | REDUCE-IT (2019): HR 0.75, NNT 21 over 4.9 y, ↓ CV death | ↑ AF and peripheral oedema; purified EPA only |
| bempedoic acid 180 mg daily | ~20% (16–22%) | CLEAR Outcomes (2023): statin-intolerant, MACE-4 HR 0.87 | gout, cholelithiasis, tendon rupture; raises simvastatin levels (≤20 mg) |
| micronised fenofibrate | — | no new CCS 2021 recommendation | TG ≥10 mmol/L or TG-related pancreatitis |
| bile acid sequestrant | modest | inconclusive | alternative to ezetimibe |
- statin intolerance: rechallenge at a lower dose or different statin first; bempedoic acid is the only non-statin with outcome data in statin intolerance (CLEAR Outcomes); ezetimibe or PCSK9 inhibitor lower LDL but lack replacement-outcome data
- inclisiran (twice-yearly siRNA): ~50% LDL lowering, outcome trials pending → second-line to PCSK9 antibodies
triglycerides
- TG >1.5 mmol/L → LDL-C underestimates atherogenic particle number (TG-rich, small dense LDL; remnants) → screen and follow with non-HDL or apoB (strong)
- Non-fasting lipids for screening and follow-up, except known TG >4.5 → fasting sample
- TG 1.5–5.6 on maximally tolerated statin + ASCVD, or diabetes + ≥1 risk factor → icosapent ethyl (strong); preferentially ≥45 y (or ≥50 with a risk factor)
- Mixed EPA/DHA at the same dose failed — STRENGTH (2020) → REDUCE-IT result does not extend to other omega-3 products
- OTC omega-3 / fish oil → not for CV risk reduction (strong)
- severe hypertriglyceridaemia (≥5.7 mmol/L, especially ≥10) or TG-related pancreatitis → fenofibrate to prevent pancreatitis
special populations
- After pregnancy complications (hypertensive disorders, gestational diabetes, preterm birth, stillbirth, low birthweight, abruption) → lipid panel late postpartum (strong); preeclampsia ≈ 2× premature ASCVD at 10–15 years. Use CV age / lifetime risk, not 10-year FRS, for statin decisions
- Reproductive age on a statin: prefer hydrophilic agents (rosuvastatin, pravastatin); effective contraception; stop before planned pregnancy or at a positive test, resume after breastfeeding
- Heterozygous FH: PCSK9 inhibitor if above the FH threshold despite statin ± ezetimibe — covered by most provincial plans (unlike ASCVD)
- Dialysis: not a statin-indicated condition — no initiation for CKD alone
- Elevated Lp(a): earlier, more intensive risk-factor management; in ASCVD favours PCSK9 inhibitor → lipoprotein(a)
monitoring
- TG <1.5 → follow LDL, non-HDL or apoB; TG ≥1.5 → non-HDL or apoB
- lipids 4–12 weeks after starting or changing therapy, then every 6–12 months
- Reassess FRS every 5 years (40–75) or when risk status changes
Prepared 2026-10-22. Not yet verified — check every number against the sources.